Assessment of changes in patient function, measured by the health assessment questionnaire - Disability index (HAQ-DI), following daily subcutaneous (SC) injections of kineret (TM) (anakinra-recombinant interleukin-1 receptor antagonist) in a standard practice population of patents with rheumatoid arthritis (RA)

Authors

Cividino A; Russell A; Offer R; Pirc L; Choquette D

pp. 1878-1878

J RHEUMATOL PUBL CO

August 1, 2003

Annual Meeting of the Canadian-Rheumatology-Association

LAKE LOUISE, CANADA

February 23, 2003

JOURNAL OF RHEUMATOLOGY

0315-162X

Alfred Cividino